MINISO Group Holding Ltd vs ResMed Inc. — how do they compare? MINISO Group Holding Ltd trades at $12.61 (market cap $3.87B), while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 7.4× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.21%). Which is the better fit depends on your goals.
| MNSO | RMD | |
|---|---|---|
Market Cap | $3.87B | $28.81B |
Sector | Technology | Health |
52-Week High | $26.63 | $293.73 |
52-Week Low | $11.30 | $182.82 |
Enterprise Value | $4.54B | $27.99B |
Dividend Yield | 5.21% | 1.21% |
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating EPS estimates with $0.591 versus $0.238 expected, and announced a HK$2 billion share repurchase program on June 29, 2026 (PRNewsWire). Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 13.02, indicating reasonable valuation.
The outlook is positive with projected revenue growth to $22.7 billion in 2026 and net profit doubling to $2.0 billion. However, risks include margin compression from rising expenses and mixed earnings history with two recent misses. Analyst consensus is 75% buy, but competitive pressures in retail remain a concern for sustained profitability.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Trailing returns across standard periods
Latest headlines on both assets
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →